A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US Cohorts

Cancer Prevention Research Unit, Department of Oncology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (MNP)
JNCI Journal of the National Cancer Institute (Impact Factor: 12.58). 01/2013; 105(2):95-103. DOI: 10.1093/jnci/djs474
Source: PubMed


The adipocyte-secreted hormone adiponectin has insulin-sensitizing and anti-inflammatory properties. Although development of pancreatic cancer is associated with states of insulin resistance and chronic inflammation, the mechanistic basis of the associations is poorly understood.Methods
To determine whether prediagnostic plasma levels of adiponectin are associated with risk of pancreatic cancer, we conducted a nested case-control study of 468 pancreatic cancer case subjects and 1080 matched control subjects from five prospective US cohorts: Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. Control subjects were matched to case subjects by prospective cohort, year of birth, smoking status, fasting status, and month of blood draw. All samples for plasma adiponectin were handled identically in a single batch. Odds ratios were calculated with conditional logistic regression, and linearity of the association between adiponectin and pancreatic cancer was modeled with restricted cubic spline regression. All statistical tests were two-sided.ResultsMedian plasma adiponectin was lower in case subjects versus control subjects (6.2 vs 6.8 µg/mL, P = .009). Plasma adiponectin was inversely associated with pancreatic cancer risk, which was consistent across the five prospective cohorts (P (heterogeneity) = .49) and independent of other markers of insulin resistance (eg, diabetes, body mass index, physical activity, plasma C-peptide). Compared with the lowest quintile of adiponectin, individuals in quintiles 2 to 5 had multivariable odds ratios ([ORs] 95% confidence intervals [CIs]) of OR = 0.61 (95% CI = 0.43 to 0.86), OR = 0.58 (95% CI = 0.41 to 0.84), OR = 0.59 (95% CI = 0.40 to 0.87), and OR = 0.66 (95% CI = 0.44 to 0.97), respectively (P (trend) = .04). Restricted cubic spline regression confirmed a nonlinear association (P (nonlinearity) < .01). The association was not modified by sex, smoking, body mass index, physical activity, or C-peptide (all P (interaction) > .10).Conclusions
In this pooled analysis, low prediagnostic levels of circulating adiponectin were associated with an elevated risk of pancreatic cancer.

Download full-text


Available from: Michael Pollak, Jul 30, 2015
10 Reads
  • Source
    • "Types of cancer; area and stage of tumor Adiponectin levels in patients Adiponectin levels in healthy persons Reference Esophageal cancer 78.0 AE 20.2 ng/mL (N = 30; males) 10.1 AE 27.7 ng/mL (N = 17; males) (p < 0.001) [78] 74.5 AE 20.2 ng/mL (N = 32; females) 95.1 AE 21.0 ng/mL (N = 13; females) (p < 0.001) [78] Liver cancer 15.11 AE 9.62 (N = 65) (p < 0.01) 11.69 AE 6.04 (N = 165) [92] 11.04 (N = 100) (p < 0.001) 30.85 (N = 30) [97] Gastric cancer 9.1 AE 6.2 ng/mL (N = 75) 13.3 AE 9.4 ng/mL (p < 0.01) [107] Upper gastric cancer 5.5 AE 4.1 ng/mL Middle gastric cancer 9.7 AE 6.4 ng/mL Lower gastric cancer 10.7 AE 4.1 ng/mL Stage 1 9.9 AE 6.9 ng/mL Stage II 8.7 AE 5.5 ng/mL Stage III 8.6 AE 4.1 ng/mL Stage IV 5.2 AE 6.2 ng/mL 7.4 AE 5.0 ng/mL (N = 68) AdipoR1 positive 8.0 AE 5.1 ng/mL (N = 28) AdipoR1 negative [103] 7.9 AE 5.5 ng/mL (N = 72) AdipoR2 positive 8.0 AE 5.1 ng/mL (N = 28) AdipoR2 negative Pancreatic cancer <4.4 mg/mL Odds ratio of 0.62 (95% CI = 0.45–0.83) (N = 468) !4.4 mg/mL (N = 1080) [112] 9.7 AE 3.8 mg/mL (N = 452) 10.0 AE 4.2 mg/mL (N = 452) [113] Males: 8.5 AE 2.9 8.5 AE 2.9 Females: 10.8 AE 4.2 11.5 AE 4.8 Colorectal cancer (CRC) 8.3 mg/mL (N = 60; metastatic tumors) 13.1 mg/mL (N = 60; non-metastatic tumors) [119] 7.4 AE 2.1 mg/mL (N = 179) 7.8 AE 1.9 mg/mL (N = 356) [120] Women: 8.04 (5.31–11.08) (N = 346) p = 0.18 Men: 4.99 (3.30–6.89) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adiponectin is produced in the white adipose tissue and is known to have anti-metabolic and anti-inflammatory properties. Serum/plasma adiponectin levels depend on diet, physical activity, and inheritance. Epidemiologic observations suggest a potential link between obesity and gastrointestinal malignancies. Low levels of adiponectin, which are known to occur in obesity, may contribute to the high incidence of cancer in this population. This review discusses the biochemical and molecular evidence regarding the relationship between adiponectin and gastrointestinal carcinogenesis and provides several future perspectives on the role of adiponectin as a target for prevention and therapy.
    Cytokine & Growth Factor Reviews 06/2014; 26(1). DOI:10.1016/j.cytogfr.2014.06.007 · 5.36 Impact Factor
  • Source
    • "Interestingly, several cancer cell types express the adiponectin receptors AdipoR1 and AdipoR2 that may mediate the inhibitory effects of adiponectin on cellular proliferation (Kim et al., 2010). Epidemiologic studies show that low levels of adiponectin have an inverse association with the risk for the development of multiple cancers as well as advanced progression of disease (Wei et al., 2005; Barb et al., 2007; Bao et al., 2013). In a prospective analysis, adiponectin levels were inversely associated with endometrial (Dal Maso et al., 2004) and breast cancer risk in postmenopausal women (Tworoger et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation and altered immune response are important components of obesity and contribute greatly to the promotion of obesity-related metabolic complications, especially cancer development. Adipose tissue expansion is associated with increased infiltration of various types of immune cells from both the innate and adaptive immune systems. Thus, adipocytes and infiltrating immune cells secrete pro-inflammatory adipokines and cytokines providing a microenvironment favorable for tumor growth. Accumulation of B and T cells in adipose tissue precedes macrophage infiltration causing a chronic low-grade inflammation. Phenotypic switching toward M1 macrophages and Th1 T cells constitutes an important mechanism described in the obese state correlating with increased tumor growth risk. Other possible synergic mechanisms causing a dysfunctional adipose tissue include fatty acid-induced inflammation, oxidative stress, endoplasmic reticulum stress, and hypoxia. Recent investigations have started to unravel the intricacy of the cross-talk between tumor cell/immune cell/adipocyte. In this sense, future therapies should take into account the combination of anti-inflammatory approaches that target the tumor microenvironment with more sophisticated and selective anti-tumoral drugs.
    Frontiers in Physiology 10/2013; 4:275. DOI:10.3389/fphys.2013.00275 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Some authors suggest that adipocytokines contribute to the induction of pancreatic carcinogenesis as well as the development of endocrine insufficiency. We evaluate the circulating concentrations of leptin, resistin and visfatin in patients with newly diagnosed pancreatic cancer (PC) and relationship between serum adipocytokines level and clinicopathological features of PC. Moreover the usefulness of those adipocytokines as possible biomarkers of endocrine pancreatic function in PC has been assessed. The pilot study group consisted of 45 individuals (mean age 65.6 ± 11.5 years, BMI 21.8 ± 3.4 kg/m(2)) with newly diagnosed PC (within last 1-3 months) and 13 healthy individuals with age, gender and BMI matched to the study group. Among PC patients 18 (40%) had recently diagnosed diabetes. Fasting plasma leptin, resistin, visfatin concentrations were determined with ELISA (R&D Systems, Phoenix Pharmaceuticals) and insulin by RIA (DakoCytomation). Patients with PC as compared to controls had significantly lower plasma leptin (40.6 ± 21.3 vs 63.2 ± 16.3 pg/mL; p < 0,0008). In contrast PC patients showed more than six fold higher level of resistin (126.2 ± 143.2 vs 18.9 ± 7.2 ng/mL; p < 0.009) than controls. The median plasma visfatin was 2.8 ± 1.8 ng/mL, which was not significantly different from the controls (3.8 ± 1.1 ng/mL). When PC patients with and without diabetes were considered separately, plasma leptin concentrations among nondiabetic patients were slightly, but not significantly higher (44.6 ± 21.0) as compared to diabetics (34.5 ± 20.7). Moreover there was no difference between visfatin and resistin level in PC, among patients with and without diabetes. No significant differences between serum level of leptin, visfatin and resistin and age, gender, BMI, smoking status, tumor localization, distant metastases and pain has been found. The results of this study confirm previous findings that patients with newly diagnosed pancreatic cancer are characterized with lower level of leptin. This pilot study showed significantly higher resistin concentrations in patients with PC in comparison to healthy controls, which may be helpful in PC early diagnosis. Changes in leptin and resistin level in PC are not likely related to endocrine disorders.
    Pancreatology 07/2013; 13(4):409-14. DOI:10.1016/j.pan.2013.04.198 · 2.84 Impact Factor
Show more